Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. Year to date metric has recorded a loss of -12.51%.However, over the last six months, we can see a weaker performance of 34.78%. Over the last 30 days, the price of XFOR has fallen by 86.67%. And in the last five days, it has surged by 27.12%.
X4 Pharmaceuticals Inc ‘s stock market performance has been somewhat erratic. The company’s stock reached a 1-year high price of $1.60 on 04/03/24, while the lowest value for the same period was recorded at $0.26 on 11/13/24.
52-week price history of XFOR Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. X4 Pharmaceuticals Inc’s current trading price is -54.15% away from its 52-week high, while its distance from the 52-week low is 180.86%. The stock’s price range during this time has been between $0.26 and $1.60. The trading volume for the Healthcare sector company’s shares reached about 1.66 million for the day, which was lower than the average daily volume of 3.4 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
X4 Pharmaceuticals Inc (XFOR) has experienced a quarterly rise of 15.49% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 125.11M and boasts a workforce of 93 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5869, with a change in price of +0.0821. Similarly, X4 Pharmaceuticals Inc recorded 2,451,436 in trading volume during the last 100 days, posting a change of +12.60%.
XFOR’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for XFOR stands at 1.31. Similarly, the long-term debt-to-equity ratio is also 1.29.
XFOR Stock Stochastic Average
Today, X4 Pharmaceuticals Inc’s raw stochastic average for the past 50 days stands at 74.62%, indicating a rise from the raw stochastic average of the last 20 days, which was 70.36%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 81.20% and 80.21% respectively.
